SCHEMBL15832016

SCHEMBL15832016

Cc1ccc(C#N)c(-c2cccnc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
XDH P47989 1/20 0.46
CYP11B2 P19099 1/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
CLK1 P49759 1/20 0.46
SCN9A Q15858 1/20 0.46
MAP2K4 P45985 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP3A4 P08684 3/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15856477 0.80 ALDH1A1 (0.54) MAOAMAOBHPGDKDM4EALDH1A1
SCHEMBL3424504 0.80 CYP2A6 (0.56) CYP2A6MAOAMAOBHPGDKDM4E
SCHEMBL25871383 0.80 CYP2A6 (0.56) CYP2A6MAOAMAOBHPGDKDM4E
SCHEMBL31663540 0.79 CNR1 (0.50) XDHCYP11B2KDM4EALDH1A1SCN9A
SCHEMBL23606173 0.78 AR (0.55) MAOBHPGDKDM4EALDH1A1NPC1
SCHEMBL14856915 0.78 ESR2 (0.55) CYP2A6CYP11B2HPGDKDM4EALDH1A1
SCHEMBL14003400 0.78 CYP2A6 (0.54) CYP2A6MAOAMAOBCYP11B2HPGD
SCHEMBL29487253 0.78 CYP11B2 (0.58) CYP2A6XDHCYP11B2HPGDKDM4E
SCHEMBL31264147 0.78 ESR2 (0.55) CYP2A6CYP11B2HPGDKDM4EALDH1A1
SCHEMBL30630392 0.78 ESR2 (0.55) CYP2A6CYP11B2HPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179686-A1 Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations GRUENENTHAL GMBH (DE) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179686-A1 Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations TRPV1, TRPV5, TRPV2 CYP2A6 1212/4885MAOA 2157/4885MAOB 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.